Strategic Key Performance Indicators for AI in Lead Optimization
ChemMedChem · 27.03.2026 · 21 (6)
DOI: 10.1002/cmdc.202501089 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 22.03.2026. Verfasst von Theodor Theis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riß, Germany. Hauptthemen laut MEDLINE: Artificial Intelligence, Drug Discovery. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
With increasing cost and failure rates in the pharmaceutical R&D process not fundamentally improving over the last decade, pressure remains high to increase the probability of success to improve the effectiveness of pharmaceutical R&D. The broad introduction of AI into the R&D landscape over the last years holds the promise to lift pharmaceutical R&D out of its productivity problem, as preliminary analyses suggest that “AI‐native” companies may be outpacing traditional peers. However, harnessing this potential requires moving beyond measuring technical model performance (e.g., predictive accuracy) to measuring strategic impact. In this perspective, members of the EFMC 2 community—focused on advancing the collaboration between computational and medicinal chemists—discuss the challenges of applying key performance indicators (KPIs) in the idiosyncratic environment of drug discovery. We argue that the shift from expert‐driven computer‐aided drug design (CADD) to semiautonomous AI necessitates a new framework of impact‐oriented KPIs. We provide recommendations for designing these strategic indicators to drive adoption, foster innovation, and objectively assess whether digital tools are delivering top‐line impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riß, Germany.
- Novartis Institute of Biomedical Research, Novartis AG, Basel, Switzerland.
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- Medicinal Chemistry, Research & Early Development, Respiratory & Immunology, BioPharmaceutical R&D, AstraZeneca, Mölndal, Sweden.
- Digital Life Science Chemistry, Nuvisan ICB GmbH, Berlin, Germany.
- Merck KGaA, Darmstadt, Germany.
ORCID-Profile: Theodor Theis, Stefanie Flohr
Zitieren
APA
Theis, T., Flohr, S., Binch, H., Czechtizky, W., Chudyk, E., Klein, M., Krier, M., & von Nussbaum, F. (2026). Strategic Key Performance Indicators for AI in Lead Optimization. ChemMedChem, 21(6). https://doi.org/10.1002/cmdc.202501089
Vancouver
Theis T, Flohr S, Binch H, Czechtizky W, Chudyk E, Klein M, et al. Strategic Key Performance Indicators for AI in Lead Optimization. ChemMedChem. 2026;21(6). doi:10.1002/cmdc.202501089
BibTeX
@article{Theis2026,
author = {Theis, Theodor and Flohr, Stefanie and Binch, Hayley and Czechtizky, Werngard and Chudyk, Ewa and Klein, Markus and Krier, Mireille and von Nussbaum, Franz},
title = {Strategic Key Performance Indicators for AI in Lead Optimization},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {6},
doi = {10.1002/cmdc.202501089}
}
EUVIMED